We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

NasdaqCM - Delayed Quote USD

Telomir Pharmaceuticals, Inc. (TELO)

4.2000

-0.2400

(-5.41%)

At close: November 20 at 4:00 PM EST

4.5000

+0.30

(+7.14%)

Pre-Market: 7:28 AM EST

Key Events

Loading Chart for TELO

9/21 12:03 PM

DELL

Previous Close 4.4400
Open 4.4000
Bid 4.1400 x 100
Ask 4.2400 x 100
Day's Range 3.8200 - 4.4052
52 Week Range 3.1100 - 20.7200
Volume 96,468
Avg. Volume 122,953
Market Cap (intraday) 124.361M
Beta (5Y Monthly) --
PE Ratio (TTM) --
EPS (TTM) -0.7700
Earnings Date Nov 12, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

telomirpharma.com

1

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

Telomir Pharmaceuticals Insider Ups Holding During Year

Telomir Pharmaceuticals Insider Ups Holding During Year

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

Individual investors are Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) biggest owners and were rewarded after market cap rose by US$24m last week

Individual investors are Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) biggest owners and were rewarded after market cap rose by US$24m last week

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET

New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET

Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TELO

40.00%

S&P 500

17.72%

1-Year Return

TELO

40.00%

S&P 500

17.72%

3-Year Return

TELO

40.00%

S&P 500

17.72%

5-Year Return

TELO

40.00%

S&P 500

17.72%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Telomir Pharmaceuticals, Inc.

4.2000

-5.41%

Mkt Cap 124.361M

Industry Biotechnology

Dogwood Therapeutics, Inc.

2.4300

-6.18%

Mkt Cap 3.237M

Industry Biotechnology

8.90

-11.09%

Mkt Cap 28.923M

Industry Biotechnology

2.0400

+6.25%

Mkt Cap 120.122M

Industry Biotechnology

Eterna Therapeutics Inc.

0.6147

-9.82%

Mkt Cap 31.58M

Industry Biotechnology

Gain Therapeutics, Inc.

1.6600

-3.49%

Mkt Cap 44.032M

Industry Biotechnology

Celularity Inc.

2.9400

+0.68%

Mkt Cap 64.696M

Industry Biotechnology

Kairos Pharma, Ltd.

1.4600

-0.68%

Mkt Cap 18.756M

Industry Biotechnology

Tharimmune, Inc.

2.5000

+2.88%

Mkt Cap 3.715M

Industry Biotechnology

Aptorum Group Limited

0.7360

-1.22%

Mkt Cap 4.128M

Industry Biotechnology

Pyxis Oncology, Inc.

3.8200

-8.17%

Mkt Cap 227.159M

Industry Biotechnology

Valuation Measures

    Annual 

As of 11/20/2024

Market Cap

124.36M
Enterprise Value

124.46M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

281.31
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-204.69%
Return on Equity (ttm)

-1,752.69%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-22.96M
Diluted EPS (ttm)

-0.7700

Balance Sheet and Cash Flow

Total Cash (mrq)

834.64k
Total Debt/Equity (mrq)

21.14%
Levered Free Cash Flow (ttm)

213.65k

TELO does not have Company Insights

FBLG FibroBiologics, Inc.

2.2400

-5.88%

GUTS Fractyl Health, Inc.

2.0600

-5.94%

MGX Metagenomi, Inc.

1.6500

-2.37%

ZJYL Jin Medical International Ltd.

1.0100

-16.53%

KYTX Kyverna Therapeutics, Inc.

4.1200

+0.98%

ANRO Alto Neuroscience, Inc.

4.2700

-4.69%

AVBP ArriVent BioPharma, Inc.

27.41

-0.04%

MIRA MIRA Pharmaceuticals, Inc.

1.2650

-9.64%

SUGP SU Group Holdings Limited

1.8400

-8.46%

CCTG CCSC Technology International Holdings Limited

1.7300

+2.98%

CHRO Channel Therapeutics Corporation

0.6192

+14.45%

DHAI DIH Holding US, Inc.

0.9001

+1.13%

GDC GD Culture Group Limited

2.5900

-3.00%

SGMT Sagimet Biosciences Inc.

4.5200

+2.49%

UMAC Unusual Machines, Inc.

3.7900

+31.60%

ACRV Acrivon Therapeutics, Inc.

6.50

+1.88%